dc.contributor.author | Fountzilas, George | en |
dc.contributor.author | Papadimitriou, C. | en |
dc.contributor.author | Dafni, U. | en |
dc.contributor.author | Bafaloukos, Dimitrios | en |
dc.contributor.author | Skarlos, Dimosthenis V. | en |
dc.contributor.author | Moulopoulos, L. A. | en |
dc.contributor.author | Razi, E. D. | en |
dc.contributor.author | Kalofonos, H. P. | en |
dc.contributor.author | Aravantinos, Gerasimos | en |
dc.contributor.author | Briassoulis, E. Ch | en |
dc.contributor.author | Papakostas, P. | en |
dc.contributor.author | Abela, K. | en |
dc.contributor.author | Gogas, H. | en |
dc.contributor.author | Kosmidis, Paraskevas A. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Dimopoulos, M. A. | en |
dc.creator | Fountzilas, George | en |
dc.creator | Papadimitriou, C. | en |
dc.creator | Dafni, U. | en |
dc.creator | Bafaloukos, Dimitrios | en |
dc.creator | Skarlos, Dimosthenis V. | en |
dc.creator | Moulopoulos, L. A. | en |
dc.creator | Razi, E. D. | en |
dc.creator | Kalofonos, H. P. | en |
dc.creator | Aravantinos, Gerasimos | en |
dc.creator | Briassoulis, E. Ch | en |
dc.creator | Papakostas, P. | en |
dc.creator | Abela, K. | en |
dc.creator | Gogas, H. | en |
dc.creator | Kosmidis, Paraskevas A. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Dimopoulos, M. A. | en |
dc.date.accessioned | 2018-06-22T09:53:06Z | |
dc.date.available | 2018-06-22T09:53:06Z | |
dc.date.issued | 2001 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41658 | |
dc.description.abstract | Purpose: To compare the efficacy of two different schedules of epirubicin and paclitaxel, as first-line chemotherapy, in patients with advanced breast cancer (ABC). Patients and Methods: From October 1997 until May 1999, 183 eligible patients with ABC entered the study. Chemotherapy in group A (93 patients) consisted of four cycles of epirubicin at a dose of 110 mg/m2 followed by four cycles of paclitaxel at a dose of 225 mg/m2 in a 3-hour infusion. All cycles were repeated every 2 weeks with granulocyte colony-stimulating factor support. The therapeutic regimen in group B (90 patients) consisted of epirubicin (80 mg/m2) immediately followed by paclitaxel (175 mg/m2 in a 3-hour infusion) every 3 weeks for six cycles. Results: In total, 79 patients (85%) in group A and 72 patients (80%) in group B completed treatment. The median relative dose-intensity of epirubicin was 0.96 in both groups, and that of paclitaxel was 0.96 and 0.97 in groups A and B, respectively. The complete response rate was higher in group A (21.5% v 9% P = .02). Nevertheless, there was no significant difference in the overall response rate between the two groups (55% v 42%, P = .10). Severe neutropenia was more frequently observed with concurrent treatment. After a median follow-up of 16.5 months, median time to progression was 10 months in group A and 8.5 months in group B (P = .27), and median survival was 21.5 and 20 months, respectively (P = .17). Conclusion: The present study failed to demonstrate a significant difference in overall response rate between dose-dense sequential administration of epirubicin and paclitaxel compared with the combination of the two drugs given on the same day, even though the sequential treatment resulted in a significantly higher complete response rate. © 2001 by American Society of Clinical Oncology. | en |
dc.language.iso | eng | en |
dc.source | Journal of Clinical Oncology | en |
dc.subject | Article | en |
dc.subject | Male | en |
dc.subject | Human | en |
dc.subject | Aged | en |
dc.subject | Humans | en |
dc.subject | Adult | en |
dc.subject | Breast cancer | en |
dc.subject | Breast neoplasms | en |
dc.subject | Controlled study | en |
dc.subject | Female | en |
dc.subject | Major clinical study | en |
dc.subject | Middle aged | en |
dc.subject | Advanced cancer | en |
dc.subject | Cancer combination chemotherapy | en |
dc.subject | Cancer survival | en |
dc.subject | Disease progression | en |
dc.subject | Follow up | en |
dc.subject | Paclitaxel | en |
dc.subject | Priority journal | en |
dc.subject | Antineoplastic combined chemotherapy protocols | en |
dc.subject | Clinical trial | en |
dc.subject | Controlled clinical trial | en |
dc.subject | Drug efficacy | en |
dc.subject | Granulocyte colony-stimulating factor | en |
dc.subject | Neutropenia | en |
dc.subject | Recombinant granulocyte colony stimulating factor | en |
dc.subject | Treatment outcome | en |
dc.subject | Survival analysis | en |
dc.subject | Drug administration schedule | en |
dc.subject | Randomized controlled trial | en |
dc.subject | Dose-response relationship | en |
dc.subject | Drug | en |
dc.subject | Epirubicin | en |
dc.subject | Dose time effect relation | en |
dc.title | Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: A randomized study conducted by the hellenic cooperative oncology group | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1200/JCO.2001.19.8.2232 | |
dc.description.volume | 19 | |
dc.description.issue | 8 | |
dc.description.startingpage | 2232 | |
dc.description.endingpage | 2239 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Aravantinos, Gerasimos [0000-0002-2106-1713] | |
dc.contributor.orcid | Kalofonos, H. P. [0000-0002-3286-778X] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |
dc.gnosis.orcid | 0000-0002-2106-1713 | |
dc.gnosis.orcid | 0000-0002-3286-778X | |